http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yhim, Ho-Young,Han, Sae-Won,Oh, Do-Youn,Han, Wonshik,Im, Seock-Ah,Kim, Tae-You,Kim, Young Tae,Noh, Dong-Young,Chie, Eui Kyu,Ha, Sung Whan,Park, In Ae,Bang, Yung-Jue Wiley Subscription Services, Inc., A Wiley Company 2010 Cancer Vol.116 No.12
<B>BACKGROUND:</B><P>The aim of this study was to evaluate the clinical treatment outcomes of recurrent breast cancer with a limited number of isolated lung metastases, and to evaluate the role of pulmonary metastasectomy.</P><B>METHODS:</B><P>The authors consecutively enrolled 140 recurrent breast cancer patients with isolated lung metastasis from 1997 to 2007 in Seoul National University Hospital and retrospectively analyzed 45 patients who had <4 metastatic lesions.</P><B>RESULTS:</B><P>Fifteen patients had pulmonary metastasectomy followed by systemic treatment (pulmonary metastasectomy group), and 30 received systemic treatment alone (nonpulmonary metastasectomy group). The 3-year progression-free survival (PFS) and 4-year overall survival (OS) was significantly longer in the pulmonary metastasectomy group than in the nonpulmonary metastasectomy group (3-year PFS, 55.0% vs 4.5%, P < .001; 4-year OS, 82.1% vs 31.6%, P = .001). In multivariate analysis, a disease-free interval (DFI) of <24 months (hazard ratio [HR], 4.53; 95% CI, 1.72-11.90), no pulmonary metastasectomy (HR, 9.52; 95% CI, 3.34-27.18) and biologic subtypes such as human epithelial growth factor receptor-2 positive (HR, 3.00; 95% CI, 1.04-8.64) and triple negative (HR, 3.92; 95% CI, 1.32-11.59) were independent prognostic factors for shorter PFS.</P><B>CONCLUSIONS:</B><P>The authors' results demonstrated that DFI and biologic subtypes of tumor are firm, independent, prognostic factors for survival, and pulmonary metastasectomy can be a reasonable treatment option in this population. Further prospective studies are warranted to evaluate the role of pulmonary metastasectomy. Cancer 2010. © 2010 American Cancer Society.</P>
Yoon, Young-Kwang,Kim, Hwang-Phill,Han, Sae-Won,Oh, Do Youn,Im, Seock-Ah,Bang, Yung-Jue,Kim, Tae-You Wiley Subscription Services, Inc., A Wiley Company 2010 Molecular carcinogenesis Vol.49 No.4
<P>KRAS is frequently mutated in nonsmall cell lung cancer (NSCLC), resulting in the activation of the MAPK/ERK kinase (MEK)/ERK pathway. High-throughput mutation profile has shown that lung cancer frequently harbors comutation of cancer-related genes. Therefore, given that cancer cells have multiple genetic alterations, combinatorial therapeutic strategy is demanded for effective cancer therapy. To address this, we first characterized MEK dependence in four NSCLC cells. Two cells (H358, A549) carried KRAS mutation only, and the other two (H23, H157) harbored comutation of KRAS/PTEN. H358 cells with KRAS mutation only were sensitive to MEK inhibition. However, the other KRAS mutant A549 cells were resistant to MEK inhibition. Previously, we have shown that dual inhibition of EGFR and MEK signaling shows a synergistic effect on KRAS mutant gastric cancer cells by suppressing compensatory activation of AKT. Here we also observed that this combination was effective in KRAS mutant A549 cells. However, the combination was ineffective in H23 and 157 cells with comutation of KRAS/PTEN. Compared to KRAS mutant/PTEN wild-type cells, signal transducer and activator of transcription 3 (STAT3) was significantly activated following MEK inhibition in KRAS/PTEN comutant cells. Combined STAT3 inhibition by a JAK2 inhibitor or gene knockdown with MEK inhibition blocked STAT3 activation, synergistically suppressed cell growth, and induced apoptosis in comutant cells. Taken together, our study provides molecular insights that help explain the heterogeneous response to MEK inhibition in KRAS mutant lung cancers, and presents a rationale for the clinical investigation of combination of MEK and EGFR inhibitor or MEK and JAK2 inhibitor depending on PTEN status. © 2010 Wiley-Liss, Inc.</P>
비호지킨림프종 환자에서 항암화학요법중 발생한 카포시육종 1 예
박영석,허대석,김철우,김노경,서창인,방영주,김병국,박선양,김태유,서지영 대한내과학회 1992 대한내과학회지 Vol.43 No.1
Kaposi`s sarcoma is generally regarded as a rare vascular tumor affecting the skin and subcutaneous tissues, but capable of involving many viscera. Once it was a rare tumor primarily affecting the elderly of Jewish and Mediterranean ancestry. But with the advent of immunosuppressive therapy, the tumor was frequently found in patients receiving these therapy sometimes with deadly results. Also it became the focus of many peoples attention when it became known that it is associated with the acquired immune deficiency syndrome. We recently experienced a case of a 34-year-old patient with non-Hodgkin`s lymphoma who after receiving seven months of anti-cancer chemotherapy, developed reddish brown papules which were proven to be Kaposi`s sarcoma pathologically and report the findings of his immunologic test results. This patients immunologic parameter tests showed that, NK cell activity which is one of the parameters of cell-mediated immunity was markedly reduced compared to normal controls. And also peripheral T4 lymphocyte count fell significantly in parallel with the aggarvation of Kaposi`s sarcoma. These findings suggest that depressed cell-mediated immunity maybe related to the development and aggravation of Kaposi`s sarcoma in this patient.
The Synergism between Belotecan and Cisplatin in Gastric Cancer
Joo Young Jung,Sang Hyun Song,Tae-Young Kim,Jung Hyun Park,Hyun-Soon Jong,Seock-Ah Im,Tae-You Kim,Yung-Jue Bang,Noe Kyoung Kim 대한암학회 2006 Cancer Research and Treatment Vol.38 No.3
Purpose: We wanted to demonstrate the anti-cancer effect and interaction between belotecan and cisplatin on gastric cancer cell line and we evaluated the mechanisms of this synergistic effect in vitro. Materials and Methods: The growth inhibitory effect of belotocan and cisplatin against several gastric cancer cell lines (SNU-5, SNU-16 and SNU-601) was estimated by tetrazolium dye assay. The effect of a combination treatment was evaluated by the isobologram method. The biochemical mechanisms for the interaction between the drugs were analyzed by measuring the formation of DNA interstrand cross-links (ICLs) and DNA topo-I activity.Results: Belotecan showed synergism with cisplatin for growth inhibitory effect on the gastric cancer cell lines SNU-5, and SNU-16, but this was subadditive on the SNU- 601 cell line. The formation of DNA ICLs in SNU-16 cells by cisplatin was increased by combination with belotecan, but this was not affected in SNU-601 cells. The topo-I inhibition by belotecan was enhanced at high concentrations of cisplatin in SNU-16, but not in SNU-601 cells.Conclusion: Belotecan and cisplatin show various combination effect against gastric cancer cells. The synergism between cisplatin and belotecan could be the result of one of the following mechanisms: the modulating effect of belotecan on the repair of cisplatin-induced DNA adducts and the enhancing effect of cisplatin on the belotecan-induced topo-I inhibitory effect. (Cancer Res Treat. 2006;38:159-167)
전이성 유방암에 대한 Cyclophosphamide , Adriamycin , Methotrexate , 5 - FU ( CAMF ) 4 제 복합화학요법
김시영(Si Young Kim),김흥태(Heung Tae Kim),강윤구(Yoon Koo Kang),서철원(Cheol Won Suh),방영주(Yung Jue Bang),김노경(Noe Kyeong Kim),이건욱(Kun Uk Lee),최국진(Kuk Jin Choe),김수태(Soo Tae Kim) 대한내과학회 1988 대한내과학회지 Vol.34 No.6
N/A Between November, 1984 and January, 1987 32 patietns with metastatic breast cancer were treated with CAMF combination chemotherapy. Median age waa 45. Fourteen patients had prior chemotherapy and 2 patients had prior endocrine therapy. The menopausal status was as follows; 13 patients were postmenopausal, 19 premenopausal. The performance status was grade 0 to 1 (ECOG) in 13 patients, 2 in 12 and 3 in 7. Treatment was cyclophosphamide 750mg/m iv, day 1, adriamycin 30mg/㎟ iv, day 1; methotrexate 40mg/㎟ iv, day 8, and 5-FV 500 mg/㎟ iv, day 9. The treatment was recycled every 4 weeks until the progression of disease. Among 32 patients, 18 (56%) achived responses (1 CR and 17 RP), Median duration of response was 9 months. Median survival for all patients was 12 months. Toxicity was as follows; leukopenia 56 %, thrombocytopenia 15%, N/V 63%. No treatmentrelated death was observed during the treatment. It was concluded that CAMF combination chemotherapy is not superior to other cornbination chemotherapy regiments, and myelosuppression is a major dose-limiting toxicity.
Kim, Dae-Young,Lee, Keun-Wook,Yun, Tak,Kim, Dong-Wan,Kim, Tae-You,Heo, Dae Seog,Bang, Yung-Jue,Kim, Noe Kyeong National Hellenic Research Foundation 2005 Oncology reports Vol.14 No.1
<P>This study was conducted to assess the efficacy of systemic chemotherapy in patients with brain metastasis from non-small cell lung cancer. Sixty-three consecutive patients who were diagnosed as having non-small cell lung cancer (NSCLC) with synchronous brain metastasis (BM) and had not been previously treated were included in this study. After cranial radiation therapy (RT), all patients in 'the chemotherapy arm' (CTX) were treated with platinum-based combination chemotherapy, and best supportive care was selected for patients in 'the no-chemotherapy arm' (no-CTX). Thirty-one of the 63 patients received systemic chemotherapy. The median age of all patients was 55 years. The performance status of all patients was ECOG grade 1-2. Twenty-two patients had a solitary brain metastasis, 37 patients had more than two masses, and 38 patients had extracranial metastatic lesions. In the CTX arm, a paclitaxel-based combination chemotherapy was administered in 38.7%, gemcitabine-based in 25.8%, and vinorelbine-based in 25.8% as the first-line chemotherapy. Seventeen patients were treated with a second-line chemotherapy, and paclitaxel plus gemcitabine was used in 8 patients. For the first-line and second-line chemotherapies, extracranial overall responses were 36 and 35%, the median response durations were 29.1 weeks (range: 9.1-58.1 weeks) and 30.4 weeks (range: 19.4-44.0 weeks), respectively. 'Progression of the extracranial lesion' (58.1%) was more frequent than an 'aggravation of neurologic status' (19.4%) for the pattern of treatment failure in the first-line chemotherapy. The causes of failure were identical in the second-line chemotherapy. The median survival of the CTX arm was longer than that of the no-CTX arm (58.1 vs. 19.0 weeks, p<0.001). Toxicity in the CTX arm was tolerable. The systemic chemotherapy showed an effectiveness to increase the survival of patients with BM from NSCLC, and extracranial progression was the main cause of chemotherapeutic failure, although consideration for non-randomized methods should be made in this study.</P>
간 및 자궁에 전이된 췌장의 Somatostatinoma
김태유,박영이,임영혁,허대석,방영주,김노경,김선희,김철우 대한내과학회 1993 대한내과학회지 Vol.44 No.5
저자등은 췌장 부위의 종양과 간과 자궁으로의 전이가 있으면서, 일반적인 췌담관계의 악성 종양과는 다른 임상경과를 갖고, 면역 화학적 조직 검사와 혈장 somatostatin의 측정으로 입증된 somatostatinoma 1예를 경험하여 보고하는 바이다. Somatostatinoma, a rare endocrine tumor, is characterized by diarrhea, steatorrhea, diagetes, and cholelithiasis due to excessive production of somatostatin. We report a case of a 32-year-old woman with pancreatic somatostatinoma that methastasized to the liver and uterus. The patient first presented with jaundice and diarrhea, and subsequently ascites and vaginal bleeding. The diagnosis was made by the pathologic examination, immunohistochemistry, and elevated plasma level of somatostatin. The patient was transiently improved with recombinant γ-interferon therapy.